Volume | 680,303 |
|
|||||
News | - | ||||||
Day High | 180.22 | Low High |
|||||
Day Low | 170.79 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Insulet Corporation | PODD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
171.41 | 170.79 | 180.22 | 180.07 | 170.79 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
21,615 | 680,303 | US$ 176.58 | US$ 120,128,162 | - | 125.82 - 298.95 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:25:00 | 3 | US$ 179.39 | USD |
Insulet (PODD) Options Flow Summary
Insulet Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
12.6B | 69.93M | - | 1.7B | 206.3M | 2.95 | 61.09 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Insulet News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PODD Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 185.38 | 188.97 | 170.67 | 180.95 | 699,748 | -5.31 | -2.86% |
1 Month | 163.32 | 193.30 | 160.19 | 174.00 | 1,057,455 | 16.75 | 10.26% |
3 Months | 163.65 | 193.30 | 160.19 | 171.56 | 877,223 | 16.42 | 10.03% |
6 Months | 186.00 | 223.56 | 160.19 | 184.00 | 891,279 | -5.93 | -3.19% |
1 Year | 293.83 | 298.95 | 125.82 | 188.85 | 1,011,263 | -113.76 | -38.72% |
3 Years | 255.48 | 335.91 | 125.82 | 230.39 | 676,497 | -75.41 | -29.52% |
5 Years | 106.57 | 335.91 | 105.92 | 216.77 | 637,915 | 73.50 | 68.97% |
Insulet Description
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide. |